Clinical Trial

CD5CAR-NK Cells for Refractory Invasive Mold Disease

Study acronym: CD5CAR-NK
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD). The study population consists of patients aged ≥18 years with refractory mold infections. The number of patients treated will be 10. This is a dose-escalation study including 3 cohorts.
Trial Details
NCT Number NCT07454122
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions Fungal Infection
Enrollment 10 participants
Start Date 2026-05
Primary Completion 2029-05 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-06